Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label spesolimab safety and efficacy in ulcerative colitis
2018-000334-35Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spesolimab in autoimmune colitis, sponsored by Boehringer Ingelheim. Primary endpoint: Exposure-adjusted rate of treatment-emergent adverse events. Started Jul 2018; status: completed.
02
Drugs
spesolimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-000334-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000334-35.